Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2016

View Archived Issues

Zalgen and NowDiagnostics collaborate on infectious disease diagnostic products

Novartis initiates phase I/II trial of MAK-683 in advanced malignancies

GlaxoSmithKline updates pipeline progress of third quarter 2016

FDA issues complete response letter for sarilumab for rheumatoid arthritis

Bird Rock Bio requests approval for phase I study of namacizumab

Final court approval for Telesta's plan of arrangement with ProMetic

EMA validates MAA for avelumab in metastatic Merkel cell carcinoma

Combination of MEDI-0680 and durvalumab feasible and active in advanced solid malignancies

KBP Bioscience's antibiotic KBP-7072 evaluated in phase I trial

Novogen licenses worldwide rights to GDC-0084 from Genentech

Japan Tobacco and Torii sign license agreement for JTE-052 in Japan

Philogen's L19TNF granted orphan drug designation in Europe

Shionogi's cefiderocol demonstrates potential for biothreat pathogens

Biogen gives update on regulatory applications for nusinersen in E.U., U.S.

EA Pharma seeks Japanese approval for budesonide rectal foam for ulcerative colitis

EMA accepts PharmaMar's MAA for plitidepsin

Astellas to acquire Ganymed

AstraZeneca exercises option for Japanese commercialization rights to benralizumab

Eisai seeks Japanese approval of twice-daily Pariet for PPI-resistant reflux esophagitis

ReViral initiates phase I trial of RV-521 to treat RSV

GlaxoSmithKline's gepotidacin effective in phase II trial for skin and skin structure infections

E-2609 begins phase III program for early Alzheimer's disease

AbbVie discloses novel TNF-alpha modulators

Hawaii Biotech describes new Botulinum neurotoxin type A light chain inhibitors

MSD files for approval of bezlotoxumab in Japan

Bayer Pharma identifies new N-lysine methyltransferase SMYD2 inhibitors

Bristol-Myers Squibb presents novel indoleamine 2,3-dioxygenase inhibitors

Pfizer submits application in Japan for palbociclib

Catabasis Pharmaceuticals describes novel treatment for cystic fibrosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...